EXOZYMES INC. Stock-Based Compensation
EXOZYMES INC. (EXOZ) reported Stock-Based Compensation of $1.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- EXOZYMES INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.22M, a 114.88% increase year-over-year.
- EXOZYMES INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $501.10K, a 57.94% increase year-over-year.
- EXOZYMES INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $677.87K, a 113.65% increase year-over-year.
- EXOZYMES INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $425.71K, a 34.18% increase year-over-year.
- EXOZYMES INC. share-based payment arrangement, noncash expense for fiscal 2025 was $1.99M, a 76.62% increase from fiscal 2024.
- EXOZYMES INC. share-based payment arrangement, noncash expense for fiscal 2024 was $1.13M, a 299.82% increase from fiscal 2023.
- EXOZYMES INC. share-based payment arrangement, noncash expense for fiscal 2023 was $281.54K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.72M 10-Q · filed 2026-08-13 | $2.40M derived: sum of 3 quarters · filed 2026-08-13 | $2.82M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $501.10K 10-Q · filed 2026-05-14 | $1.18M derived: sum of 2 quarters · filed 2026-05-14 | $1.60M derived: sum of 3 quarters · filed 2026-05-14 | $2.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $677.87K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.10M derived: sum of 2 quarters · filed 2026-03-30 | $1.67M derived: sum of 3 quarters · filed 2026-08-13 | $1.99M 10-K · filed 2026-03-30 |
| 2025-09-30 | $425.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $992.96K derived: sum of 2 quarters · filed 2026-08-13 | $1.31M 10-Q · filed 2025-11-13 | $1.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $567.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $884.53K 10-Q · filed 2026-08-13 | $1.20M derived: sum of 3 quarters · filed 2026-08-13 | $1.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $317.28K 10-Q · filed 2026-05-14 | $634.55K derived: sum of 2 quarters · filed 2026-05-14 | $951.83K derived: sum of 3 quarters · filed 2026-05-14 | $1.30M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $317.28K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $634.55K derived: sum of 2 quarters · filed 2026-03-30 | $982.83K derived: sum of 3 quarters · filed 2026-03-30 | $1.13M 10-K · filed 2026-03-30 |
| 2024-09-30 | $317.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $665.55K derived: sum of 2 quarters · filed 2025-11-13 | $808.36K 10-Q · filed 2025-11-13 | $915.46K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $348.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $491.08K 10-Q · filed 2025-08-12 | $598.18K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $142.81K 10-Q · filed 2025-05-12 | $249.91K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $107.10K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $281.54K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $174.44K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |